Lithium oral solution Rx
Generic Name and Formulations:
Lithium ion 8mEq/5mL (equivalent to 300mg lithium carbonate); contains alcohol.
Roxane Laboratories, Inc.
Indications for Lithium oral solution:
Mania in bipolar disorder.
Individualize. Acute mania: 600mg 3 times daily. Usual maintenance: 300mg 3 or 4 times daily.
Renal or cardiovascular disease, concomitant diuretics, sodium depletion, severely debilitated or dehydrated: not recommended (if necessary, use low doses, monitor serum lithium levels daily, hospitalize).
Seizure disorders. Maintain adequate fluid and salt intake, esp. with fever, sweating, diarrhea, or infection. Monitor serum lithium levels frequently (toxic and therapeutic levels are close); draw blood for serum tests 8–12 hrs after previous dose. Monitor thyroid, renal function. Discontinue if diarrhea, vomiting, tremor, ataxia, drowsiness or weakness occur. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended.
See Contraindications. Lithium toxicity potentiated by diuretics, ACE inhibitors, angiotensin II receptor blockers, carbamazepine, indomethacin, piroxicam (possibly other NSAIDs, including COX-2 inhibitors), metronidazole, calcium channel blockers: monitor and adjust lithium dose, if needed. Discontinue if signs of neurologic toxicity occur with neuroleptics (eg, haloperidol). Xanthines, acetazolamide, urea, alkalinizing agents may reduce serum lithium levels. Fluoxetine has variable effects on serum lithium levels. Prolongs effects of neuromuscular blockers. Hypothyroidism with chronic iodide administration. Serotonin syndrome with SSRIs.
Polyuria, polydipsia, drowsiness, tremor, hypothyroidism, extrapyramidal symptoms, GI upset, renal toxicity, seizures, arrhythmias, hypotension, lethargy, metallic taste, dry mouth, blurred vision, pseudotumor cerebri (discontinue if occurs).
Caps 150mg, 600mg—100; Caps 300mg—100, 1000; Tabs 300mg—100, 1000; Soln—500mL
Endocrinology Advisor Articles
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes
- Achieving Glycemic Control in T2D After Basal Insulin Initiation
- Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up
- Effects of the Two Types of Anorexia Nervosa on Bone Metabolism
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Risk for Iodine Deficiency and Hypothyroidism High in Children on Parenteral Nutrition
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- Glycemic Control Variations for Children, Adolescents With T1D in High-Income Countries
- Late-Life Mobility Limitations Linked to Obesity After Arthroplasty for OA in Women
- Fracture Risk Should Be Monitored in Bisphosphonate Drug Holiday
- Provider Counseling for Weight Loss Up for Arthritis, Overweight